BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36867078)

  • 1. Phenotypic subtypes predict outcomes in colorectal cancer.
    Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
    Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consensus molecular subtype classification of colorectal adenomas.
    Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
    J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Characterization of patients with sporadic colorectal cancer following the new Consensus Molecular Subtypes (CMS)].
    Wielandt AM; Villarroel C; Hurtado C; Simian D; Zamorano D; Martínez M; Castro M; Vial MT; Kronberg U; López-Kostner F
    Rev Med Chil; 2017 Apr; 145(4):419-430. PubMed ID: 28748988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
    Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
    Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
    Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
    Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
    Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers.
    Kim JH; Seo MK; Lee JA; Yoo SY; Oh HJ; Kang H; Cho NY; Bae JM; Kang GH; Kim S
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
    Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
    Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer.
    Dunne PD; O'Reilly PG; Coleman HG; Gray RT; Longley DB; Johnston PG; Salto-Tellez M; Lawler M; McArt DG
    Oncotarget; 2016 Jun; 7(24):36632-36644. PubMed ID: 27153559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.
    Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E
    Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry.
    Li X; Larsson P; Ljuslinder I; Ling A; Löfgren-Burström A; Zingmark C; Edin S; Palmqvist R
    Pathol Res Pract; 2021 Apr; 220():153379. PubMed ID: 33721619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy.
    Becht E; de Reyniès A; Giraldo NA; Pilati C; Buttard B; Lacroix L; Selves J; Sautès-Fridman C; Laurent-Puig P; Fridman WH
    Clin Cancer Res; 2016 Aug; 22(16):4057-66. PubMed ID: 26994146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.
    Marisa L; Svrcek M; Collura A; Becht E; Cervera P; Wanherdrick K; Buhard O; Goloudina A; Jonchère V; Selves J; Milano G; Guenot D; Cohen R; Colas C; Laurent-Puig P; Olschwang S; Lefèvre JH; Parc Y; Boige V; Lepage C; André T; Fléjou JF; Dérangère V; Ghiringhelli F; de Reynies A; Duval A
    J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study.
    Haasnoot KJC; Backes Y; Moons LMG; Kranenburg O; Trinh A; Vermeulen L; Noë M; Tuynman JB; van Lent AUG; van Ginneken R; Seldenrijk CA; Raicu MG; Trumpi K; Ubink I; Milne AN; Boonstra JJ; Groen JN; Schwartz MP; Wolfhagen FHJ; Geesing JMJ; Ter Borg F; Brosens LAA; van Bergeijk J; Spanier BWM; de Vos Tot Nederveen Cappel WH; Kessels K; Seerden TCJ; Vleggaar FP; Offerhaus GJA; Siersema PD; Elias SG; Laclé MM;
    Mod Pathol; 2020 Dec; 33(12):2626-2636. PubMed ID: 32581367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2.
    Chang K; Willis JA; Reumers J; Taggart MW; San Lucas FA; Thirumurthi S; Kanth P; Delker DA; Hagedorn CH; Lynch PM; Ellis LM; Hawk ET; Scheet PA; Kopetz S; Arts J; Guinney J; Dienstmann R; Vilar E
    Ann Oncol; 2018 Oct; 29(10):2061-2067. PubMed ID: 30412224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials.
    Fontana E; Eason K; Cervantes A; Salazar R; Sadanandam A
    Ann Oncol; 2019 Apr; 30(4):520-527. PubMed ID: 30796810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior.
    Perez-Villamil B; Romera-Lopez A; Hernandez-Prieto S; Lopez-Campos G; Calles A; Lopez-Asenjo JA; Sanz-Ortega J; Fernandez-Perez C; Sastre J; Alfonso R; Caldes T; Martin-Sanchez F; Diaz-Rubio E
    BMC Cancer; 2012 Jun; 12():260. PubMed ID: 22712570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of colorectal cancer in accordance with consensus molecular subtype classification.
    Sawayama H; Miyamoto Y; Ogawa K; Yoshida N; Baba H
    Ann Gastroenterol Surg; 2020 Sep; 4(5):528-539. PubMed ID: 33005848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refining colorectal cancer classification and clinical stratification through a single-cell atlas.
    Khaliq AM; Erdogan C; Kurt Z; Turgut SS; Grunvald MW; Rand T; Khare S; Borgia JA; Hayden DM; Pappas SG; Govekar HR; Kam AE; Reiser J; Turaga K; Radovich M; Zang Y; Qiu Y; Liu Y; Fishel ML; Turk A; Gupta V; Al-Sabti R; Subramanian J; Kuzel TM; Sadanandam A; Waldron L; Hussain A; Saleem M; El-Rayes B; Salahudeen AA; Masood A
    Genome Biol; 2022 May; 23(1):113. PubMed ID: 35538548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consensus Molecular Subtypes of Colorectal Cancer and their Clinical Implications.
    Thanki K; Nicholls ME; Gajjar A; Senagore AJ; Qiu S; Szabo C; Hellmich MR; Chao C
    Int Biol Biomed J; 2017; 3(3):105-111. PubMed ID: 28825047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.